-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] The "14th Five-Year Plan for the Development of the Pharmaceutical Industry" proposes that during the "14th Five-Year Plan" period, the R&D investment in the entire pharmaceutical industry will increase by more than 10% annually; by 2025, the new sales of innovative products will account for the entire industry.
The proportion of incremental operating income further increased
.
It is understood that in recent years, there has been a surge of innovative drugs in China.
Under the combined effect of policies, talents, markets and capital, more and more innovative drugs have been approved for marketing
.
With the continuous expansion of investment in innovative drug research and development, some of these companies are now beginning to accelerate the realization of innovative results
.
Taking Fosun Pharma as an example, its innovative pipeline is continuing to land.
For example, on March 24, 2022, the State Food and Drug Administration website showed that Fosun Pharma’s biopharmaceutical platform Fuhong Henlius’ PD-1 inhibitor slulimumab The indication is highly microsatellite unstable (MSI-H) solid tumors approved for marketing, which is the company's first approved bioinnovative drug, and the registration application for another indication (squamous non-small cell lung cancer) has also been approved.
It has been accepted by the State Food and Drug Administration
.
In addition, in 2021, the company's products such as hambetech (bevacizumab biosimilar), Yibao (human erythropoietin for injection) (new indications for the treatment of anemia caused by chemotherapy in patients with non-myeloid malignancies), etc.
batch listing
.
According to the 2021 annual report released by Fosun Pharma, in 2021, Fosun Pharma’s R&D investment will increase by 24.
28% year-on-year, totaling 4.
975 billion yuan
.
Among them, research and development expenses increased by 37.
17% year-on-year to 3.
834 billion yuan, accounting for 13.
26% of the revenue of the pharmaceutical sector
.
Judging from the performance in 2021, the revenue of Fosun Pharma's pharmaceutical segment in 2021 will increase by 32.
1% year-on-year to 28.
904 billion yuan, accounting for 74.
1%
.
The company's revenue in the pharmaceutical sector has increased significantly, mainly including Fubitai, Hanlikang, Hanquyou, Su Kexin, etc.
The revenue of new products and sub-new products accounts for more than 25% of the revenue of the pharmaceutical business, and the revenue structure has been continuously optimized. .
In addition to Fosun Pharma, Simcere Pharma recently announced in its 2021 performance report that the transformation to innovation has achieved remarkable results
.
The data shows that in 2021, Simcere's innovative drug revenue will increase by 53.
8% year-on-year, reaching 3.
120 billion yuan, accounting for 62.
4%, a new high
.
In addition, the company has a total of nearly 60 innovative drug R&D pipelines, 19 innovative drugs in the clinical stage, and the clinical development and registration work is progressing rapidly
.
It is understood that in recent years Simcere has attached great importance to and is committed to the research and development of innovative drugs.
It is guided by clinical value, insists on differentiation, continuously strengthens the target layout and product portfolio in strategically focused areas, and continues to explore patients urgently needed and possessed.
Products with huge market potential
.
The report shows that in 2021, Simcere will invest 1.
417 billion yuan in research and development, accounting for 28.
3% of its total revenue, a record high
.
Hengrui Medicine, which has also attached great importance to and continued to invest in research and development for a long time, has also significantly accelerated the pace of output of innovative results
.
If the start of 2022 is less than one month, Hengrui Medicine will launch or apply for the launch of four innovative drugs, including a class 1 new drug PD-L1 monoclonal antibody SHR-1316 (adbelimumab injection) combined with chemotherapy for first-line treatment.
The marketing application for the indication of stage small cell lung cancer was accepted
.
It is reported that at present, Hengrui Medicine has listed 10 innovative drugs, and has more than 50 innovative drugs under development.
There are more than 240 clinical trials at home and abroad, of which more than 20 innovative drug projects have been approved for global multi-center development.
Or regional clinical research, and gradually formed a virtuous cycle of innovative research and development with a batch of listing, a batch of clinical trials, and a batch of development
.
Analysts said that with the encouragement of the state for the development of innovative drugs and the continuous investment of pharmaceutical companies in innovative drugs, the market situation of new drugs in China is relatively optimistic
.
From the perspective of R&D investment, the data shows that in 2020, the R&D expenditure of listed biopharmaceutical companies in China will increase by 37.
10% year-on-year, reaching 11.
534 billion yuan
.
In the first half of 2021, the R&D expenditure of listed biopharmaceutical companies in China has reached 6.
978 billion yuan
.
The increased investment in research and development, to a certain extent, will help to speed up the transformation of enterprises' research results in biomedical products
.
The data shows that as of the end of November 2021, 25 Class 1 innovative drugs have been approved in 2021, which has exceeded the number of 20 approved innovative drugs in 2020
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The proportion of incremental operating income further increased
.
It is understood that in recent years, there has been a surge of innovative drugs in China.
Under the combined effect of policies, talents, markets and capital, more and more innovative drugs have been approved for marketing
.
With the continuous expansion of investment in innovative drug research and development, some of these companies are now beginning to accelerate the realization of innovative results
.
Taking Fosun Pharma as an example, its innovative pipeline is continuing to land.
For example, on March 24, 2022, the State Food and Drug Administration website showed that Fosun Pharma’s biopharmaceutical platform Fuhong Henlius’ PD-1 inhibitor slulimumab The indication is highly microsatellite unstable (MSI-H) solid tumors approved for marketing, which is the company's first approved bioinnovative drug, and the registration application for another indication (squamous non-small cell lung cancer) has also been approved.
It has been accepted by the State Food and Drug Administration
.
In addition, in 2021, the company's products such as hambetech (bevacizumab biosimilar), Yibao (human erythropoietin for injection) (new indications for the treatment of anemia caused by chemotherapy in patients with non-myeloid malignancies), etc.
batch listing
.
According to the 2021 annual report released by Fosun Pharma, in 2021, Fosun Pharma’s R&D investment will increase by 24.
28% year-on-year, totaling 4.
975 billion yuan
.
Among them, research and development expenses increased by 37.
17% year-on-year to 3.
834 billion yuan, accounting for 13.
26% of the revenue of the pharmaceutical sector
.
Judging from the performance in 2021, the revenue of Fosun Pharma's pharmaceutical segment in 2021 will increase by 32.
1% year-on-year to 28.
904 billion yuan, accounting for 74.
1%
.
The company's revenue in the pharmaceutical sector has increased significantly, mainly including Fubitai, Hanlikang, Hanquyou, Su Kexin, etc.
The revenue of new products and sub-new products accounts for more than 25% of the revenue of the pharmaceutical business, and the revenue structure has been continuously optimized. .
In addition to Fosun Pharma, Simcere Pharma recently announced in its 2021 performance report that the transformation to innovation has achieved remarkable results
.
The data shows that in 2021, Simcere's innovative drug revenue will increase by 53.
8% year-on-year, reaching 3.
120 billion yuan, accounting for 62.
4%, a new high
.
In addition, the company has a total of nearly 60 innovative drug R&D pipelines, 19 innovative drugs in the clinical stage, and the clinical development and registration work is progressing rapidly
.
It is understood that in recent years Simcere has attached great importance to and is committed to the research and development of innovative drugs.
It is guided by clinical value, insists on differentiation, continuously strengthens the target layout and product portfolio in strategically focused areas, and continues to explore patients urgently needed and possessed.
Products with huge market potential
.
The report shows that in 2021, Simcere will invest 1.
417 billion yuan in research and development, accounting for 28.
3% of its total revenue, a record high
.
Hengrui Medicine, which has also attached great importance to and continued to invest in research and development for a long time, has also significantly accelerated the pace of output of innovative results
.
If the start of 2022 is less than one month, Hengrui Medicine will launch or apply for the launch of four innovative drugs, including a class 1 new drug PD-L1 monoclonal antibody SHR-1316 (adbelimumab injection) combined with chemotherapy for first-line treatment.
The marketing application for the indication of stage small cell lung cancer was accepted
.
It is reported that at present, Hengrui Medicine has listed 10 innovative drugs, and has more than 50 innovative drugs under development.
There are more than 240 clinical trials at home and abroad, of which more than 20 innovative drug projects have been approved for global multi-center development.
Or regional clinical research, and gradually formed a virtuous cycle of innovative research and development with a batch of listing, a batch of clinical trials, and a batch of development
.
Analysts said that with the encouragement of the state for the development of innovative drugs and the continuous investment of pharmaceutical companies in innovative drugs, the market situation of new drugs in China is relatively optimistic
.
From the perspective of R&D investment, the data shows that in 2020, the R&D expenditure of listed biopharmaceutical companies in China will increase by 37.
10% year-on-year, reaching 11.
534 billion yuan
.
In the first half of 2021, the R&D expenditure of listed biopharmaceutical companies in China has reached 6.
978 billion yuan
.
The increased investment in research and development, to a certain extent, will help to speed up the transformation of enterprises' research results in biomedical products
.
The data shows that as of the end of November 2021, 25 Class 1 innovative drugs have been approved in 2021, which has exceeded the number of 20 approved innovative drugs in 2020
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
